Venture Capital Funding Survey, Second Quarter 2014
VENTURE CAPITAL FUNDING, SECOND QUARTER 2014 This is a listing of many of the Bay Area firms that received venture capital financing between April 1 and June 30, 2014. Most of the data was compiled from a survey conducted by PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association in conjunction with The Mercury News. In the case of some investments there may have been other participants in the round who are not credited. Also, the amounts listed may not include all venture funding the company received during the quarter. *Indicates this is a seed or first-round infusion of money from venture capitalists. These companies may have received money previously from other investors and aren't necessarily startups.
BIOTECHNOLOGY / HEALTH Investors Amount $9,333,000 Frazier Management, undisclosed firm
Description
Name Acerta Pharma
City San Carlos
Stage Startup/Seed
Aduro BioTech
Berkeley
Later Stage
$40,602,000 Johnson & Johnson Clinical research services Development, Morningside Technologies, undisclosed firm
Advanced Cardiac Therapeutics
Santa Clara
Expansion
$7,300,000 NBGI Private Equity, New Temperature-sensing Enterprise Associates cardiac ablation systems
Aldea Pharmaceuticals
Redwood City
Early Stage
$1,000,000 Canaan Partners
Pharmaceutical company
Alector
San Francisco
Startup/Seed
$3,000,000 Polaris Partners
Biotech company
Alios BioPharma
South San Francisco
Early Stage
$41,000,000 F Hoffmann La Roche AG, Novel medicines for Novartis Venture Funds, treatment of viral diseases Novo A/S, Sr One, undisclosed firm
ARMO Biosciences
Redwood City
Early Stage
$30,000,000 Duff Ackerman & Goodrich, Kleiner Perkins Caufield & Byers, NanoDimension Management, OrbiMed Advisors
Later Stage
$55,127,200 Cowen Capital Partners , Gene therapies for serious undisclosed firma, Venrock eye diseases
Avalanche Biotechnologies* Menlo Park
Page 1 of 30
Pharma treatments for cancer and autoimmune diseases
Biotechnology company